MiniMed launches its smallest automated insulin delivery system in Europe
MiniMed has begun commercial shipments of its new MiniMed Flex system across Europe, marking the launch of the company’s first app-controlled insulin pump and its smallest automated insulin delivery (AID) system to date.
The launch follows an initial customer experience phase in selected European markets, with the system now being introduced more widely across the region.
MiniMed Flex uses the same SmartGuard algorithm as the MiniMed 780G system but introduces a smaller, screenless design that allows users to manage their insulin delivery through a compatible smartphone.
The pump is approximately half the size of previous MiniMed pumps and roughly the volume of two stacked insulin vials.
It holds up to 300 units of insulin and can be used with MiniMed’s Extended infusion set, which can be worn for up to seven days.
All primary pump functions are managed through a compatible mobile app on iOS and Android devices, removing the need to interact directly with the pump throughout the day.
The system also features a rechargeable battery and supports wireless software updates, which will allow users to access future improvements, including a next-generation algorithm currently in development.
Slobodan Radumilo, Senior Vice President and Chief Commercial Officer for EMEA and APAC at MiniMed, said: “People with diabetes want strong outcomes and technology that fits their lives.
“MiniMed Flex™ combines our proven SmartGuard™ algorithm with a discreet, intuitive design to help make diabetes management easier. We look forward to expanding access in the months ahead.”
The introduction of MiniMed Flex comes as automated insulin delivery technology continues to become more widely used in diabetes care, including in the UK, where the NHS is rolling out hybrid closed-loop systems to eligible people with type 1 diabetes.
While these systems have helped reduce the daily demands of glucose management, the size and visibility of insulin pumps can remain a consideration for some users.
The smaller design and smartphone-based controls of MiniMed Flex are intended to make the technology more discreet and easier to incorporate into everyday activities.
Olof Wretling, whose 14-year-old son Otto was diagnosed with type 1 diabetes at the age of nine, said: “Our son, Otto, belongs to a generation that is used to managing everything through their phones, so this feels completely natural to him. One of the biggest changes with the MiniMed Flex is that he feels much more in control of his own diabetes management – it’s becoming more discreet and more independent. As parents, we no longer have to constantly hover around him or interfere.”
MiniMed Flex is powered by the SmartGuard algorithm, which automatically adjusts insulin delivery every five minutes based on real-time glucose readings from a compatible continuous glucose monitor.
It also includes Meal Detection technology, which identifies rapid increases in glucose levels and delivers automatic correction doses when meal boluses are occasionally missed or carbohydrate counts are underestimated.
However, the system is not fully automated, and users are still required to announce meals to help manage glucose levels after eating.
The SmartGuard algorithm is already used in the MiniMed 780G system, with real-world studies reporting positive glucose management outcomes.
Data from users of the MiniMed 780G system with recommended optimal settings have shown an average time in range of 80%, while another real-world study reported more than 90% overnight time in range.
Further findings have shown sustained improvements in glucose management over three years, with nine out of 10 users on optimal settings achieving the international target of more than 70% time in range.
Although these findings relate to the MiniMed 780G system, they are relevant to the new Flex system because both use the same SmartGuard algorithm.
Dr Sharona Azriel, a specialist in Endocrinology and Nutrition at the Infanta Sofía University Hospital in Madrid, Spain, said: “In my early experience with MiniMed Flex™, what stands out is how adults who have been living with type 1 diabetes for years respond to a pump that stays out of sight and is controlled from their phone.
“That combination of convenience and discretion changes how the device feels in their daily lives.”
MiniMed Flex is CE marked in Europe for people aged two years and older with insulin-treated diabetes, including type 1 and type 2 diabetes, and is also approved for use during pregnancy.
The system is being launched in Europe with the Simplera Sync sensor, which can be worn for up to seven days and features a two-step insertion process.
Compatibility with the Instinct sensor, manufactured by Abbott, is planned for Europe in 2027. The sensor offers up to 15 days of wear and a one-step insertion process.
The European rollout is taking place gradually, with MiniMed planning to expand access over the coming months.
Details of when the MiniMed Flex system will become available in the UK, including potential access through the NHS, have not been confirmed.
